DOCSLIB.ORG

“New Influenza Antivirals”

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
“New Influenza Antivirals” “New influenza antivirals” Aeron Hurt @hurt_lab @ WHOCCFluMelb “New influenza antivirals” Or more specifically… “Polymerase inhibitors” “Baloxavir” Aeron Hurt @hurt_lab @ WHOCCFluMelb COI declaration • Member of baloxavir publication steering committee organized by Shionogi • Research group has received funding to conduct research studies from the following antiviral companies: • Shionogi • Romark • AusBio Acknowledgments • Thanks to the following people for providing data/information/figures used in the talk: • Dr. Zuzana Dobbie, Roche, Switzerland • Dr. Takeki Uehara, Shionogi, Japan • Dr. Harsha Shetty, Seqirus, Australia Action of the ‘current’ influenza antivirals NA inhibitors Adamantanes (M2 ion channel inhibitors) Figure from Open University : http://www.open.edu/openlearn/ocw/mod/oucontent/view.php?printable=1&id=2675&extra=thumbnail_idp1455600 Action of the ‘current’ influenza antivirals Resistance currently very low, but has been seen in the past. Efficacy is moderate. Resistance across NA inhibitors virtually all Peramivir (Rapivab) circulating strains…no longer • Intravenous NA inhibitor recommended • TGA approved in Mar 2018, available in 2019 • Indicated for the treatment of acute influenza infection in adults and children 2 years and older who have been symptomatic for no more than two days* Not on PBS Adamantanes • (M2 ion channel inhibitors) • Use in hospitalised patients Figure from Open University : http://www.open.edu/openlearn/ocw/mod/oucontent/view.php?printable=1&id=2675&extra=thumbnail_idp1455600 Action of the polymerase inhibitors 3 different polymerase inhibitors that are in late-phase clinical trial or recently approved Transcription of vRNA to mRNA starts with “cap-snatching” NA inhibitors • Cellular capped RNA bound by PB2 → pimodivir • Cleaved by PA → baloxavir • Elongation by PB1 → favipiravir Adamantanes (M2 ion channel inhibitors) Polymerase inhibitors Summary of the polymerase inhibitors Baloxavir Favipiravir Pimodivir Polymerase target PA PB1 PB2 Influenza specificity A & B A, B & C A Can inhibit non-influenza viruses? No Yes No Approved for use in some countries? Yes, in Japan (Feb Yes, Japan. (But limited to No, currently in ‘18) and US (Nov pandemic use under Phase III ‘18). Many countries certain conditions). in 2019. Variable efficacy in US trials Dosing routes Oral Oral Oral Has been tested in combination with No No Yes oseltamivir in clinical trials? Ability to inhibit NAI resistant strains? Yes Yes Yes Antiviral- resistant mutants identified in vitro? Yes Yes Yes Antiviral resistant strains identified in clinical Yes No Yes trials? Efficacy of Baloxavir marboxil - Xofluza Baloxavir Long retention time Baloxavir Marboxil (half-life: 79.1 h) (pro drug) Japan Baloxavir Acid Taiwan (active form) Hydrolysis Rest of the world • Single dose delivery • US approved for uncomplicated influenza in >12 years of age • Japan also approved for use in children <12 years CAPSTONE-1: Phase III study of baloxavir vs. placebo or oseltamivir in OwH influenza patients Study design Treatment period (5 days) Follow-up period (17 days) ▪ Aged 12–64 years 2 Baloxavir 40 or 80 mg§ ▪ Otherwise healthy Aged 2 20–64 ¶ ▪ Fever (≥38°C axillary), Oseltamivir 75 mg BID years 1 ≥1 systemic symptom* and Placebo ≥1 respiratory symptom** Day 6–22 ▪ ≤48 hours from symptom 2 Aged Baloxavir 40 or 80 mg§ onset 12–19 1 N=1436 (ITTI N=1064) years Placebo Key exclusion criteria Study endpoints ▪ Hospitalisation ▪ Primary endpoint: time to alleviation of symptoms ▪ High risk of influenza complications ▪ Key secondary endpoints: virological outcomes, time to fever resolution ▪ Primary safety endpoints: incidence of TEAEs *Headache, feverishness/chills; muscle/joint pain or fatigue of moderate or greater severity. **Cough, sore throat or nasal congestion of moderate or greater severity; §Single dose on Day 1 (40 mg for body weight <80 kg, 80 mg for ≥80 kg); ¶For 5 days. Hayden et al. N Engl J Med 2018 Adapted from slide kindly provided by Zuzana Dobbie, Roche Baloxavir significantly reduced TTAS by >24 hours vs. placebo and was comparable with oseltamivir Proportion of patients with symptoms Proportion of patients with symptoms Baloxavir Baloxavir 1.0 If treatment was <24 hrs post symptom onset: 1.0 32.8 hr improvement in TTAS If treatment was >24 hrsPlacebo post symptom onset: 13.2 hr improvementOseltamivir in TTAS 0.8 Censor 0.8 Censor Baloxavir Placebo Baloxavir Oseltamivir (n=455) (n=230) (n=507) (n=514) 0.6 53.7 80.2 0.6 Median (95% CI), hours 53.5 53.8 (49.5, 58.5) (72.6, 87.1) Median (95% CI), hours (48.0, 58.5) (50.2, 56.4) Difference (95% CI), −26.5 (−35.8, −17.8) 0.4 hours 0.4 Difference (95% CI), hours −0.3 (NR) P-value* <0.001 p-value NR 0.2 0.2 Proportion Proportion of patients unalleviated 53.7 80.2 Proportion of unalleviated patients 53.5 53.8 0 0 0 30 60 90 120 150 180 210 240 270 300 330 360 0 30 60 90 120 150 180 210 240 270 300 330 360 Time from start of treatment (hours) Time from start of treatment (hours) Primary endpoint. Intention-to-treat infected patients population *Stratified generalised Wilcoxon test (stratification factors: country and symptoms score at baseline) Patients who did not experience alleviation of symptoms were censored at the last observation time point. Subset of patients whose TTAS was not missing Hayden et al. N Engl J Med 2018 Adapted from slide kindly provided by Zuzana Dobbie, Roche Baloxavir significantly reduced viral titres vs. placebo or oseltamivir from 1 day post dose Viral titre: baloxavir vs placebo Viral titre: baloxavir vs oseltamivir¶ 2 Baloxavir (n=427) 2 Baloxavir (n=352) 1 Placebo (n=210) 1 Oseltamivir (n=359) 0 0 § § re re -1 -1 aseline in aseline in aseline in aseline in -2 -2 b b irus tit irus tit v v -3 -3 -4 -4 -5 * * -5 * nfluenza nfluenza * i i * * Change from Change from -6 -6 -7 -7 -8 -8 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 Baloxavir 427 412 404 114 403 97 407 Baloxavir 427 412 404 114 403 97 407 Placebo 210 201 191 57 192 48 197 Placebo 210 201 191 57 192 48 197 (n) (n) Study Day Study Day Secondary endpoint. ITTI population § ¶ *p<0.05 vs placebo or oseltamivir; Mean log10 (TCID50/ml); Adults aged 20–64 years Hayden et al. N Engl J Med 2018 Adapted from slide kindly provided by Zuzana Dobbie, Roche The median time to cessation of viral shedding was 24 hours following baloxavir treatment Median time to cessation of viral shedding (infectious virus) Placebo 96 hours n=209 Oseltamivir 72 hours n=357* p<0.0001 Baloxavir baloxavir 24 hours vs placebo n=426** § and oseltamivir *Adults aged 20–64 years; **n=351 for comparison vs oseltamivir (adults aged 20–64 years) §Stratified generalised Wilcoxon test One day was converted into 24 hours Hayden et al. N Engl J Med 2018 Adapted from slide kindly provided by Zuzana Dobbie, Roche Baloxavir was well tolerated, with numerically fewer AEs than oseltamivir Incidence of AEs 100 Placebo (N=309) 90 Oseltamivir (N=513) 80 Baloxavir (N=610) 70 60 50 40 30 24.6 24.8 Proportion of (%) patients Proportion 20.7 20 10 0.0 0.1 0.0 0.0 0.0 0.3 0.4 0.3 0.3 0 † Any AE Death SAEs AEs leading to withdrawal of study drug *No significant differences were noted between the groups except for pre-specified comparison of treatment-related AEs, which were more common with oseltamivir than baloxavir (p=0.009) †Excluding death See slide notes for AEs reported in at least 1% of patients in any treatment group Hayden et al. N Engl J Med 2018 Adapted from slide kindly provided by Zuzana Dobbie, Roche Summary: CAPSTONE 1 and 2 CAPSTONE-1: Phase III study of OwH patients (Hayden et al. N Engl J Med, 2018) • Baloxavir was superior to placebo and comparable with oseltamivir in alleviating influenza symptoms • Baloxavir was superior to both placebo and oseltamivir in reducing viral titres and median time to the cessation of viral shedding • Baloxavir was well tolerated CAPSTONE-2: Phase III study in high-risk influenza patients of baloxavir vs placebo or oseltamivir (unpublished, Ison et al.ID Week, San Fran, 2018) • Confirmed safety in this population • Baloxavir was superior to placebo in improving influenza symptoms (29.1 hr) • For influenza B, baloxavir superior to placebo (by 26.0 hr) and oseltamivir (by 27.1 hr) • Baloxavir associated with significantly fewer influenza-related complications and reduced the requirement for antibiotics compared with placebo Frequency of resistance (or reduced susceptibility) to Baloxavir marboxil Influenza A viral variants with reduced susceptibility to baloxavir have been characterised Cells: MDBK Virus: A/WSN/33 Drug Concentrations: Start at 25xEC50, 5xEC50, 1xEC50, 0.2xEC50, 0.04xEC50. Increase the drug concentrations (x2) in each passage Omoto S et al. Scientific Reports 2018;8:9633 Noshi T. et al. Antiviral Research 2018 (in press) Viral variants conferring reduced susceptibility to baloxavir have been detected in clinical trials PA AA substitution detected and frequency Analysis Predominant Trials Population type/subtype Fold change in susceptibility (n=) <10 fold >10 fold Ph2 OwH in I38T (n=2) 182 A(H1N1)pdm09 E23K (n=1) Japan I38F (n=2) E23G (n=1) I38T (n=33) CAPSTONE-1 370 A(H3N2) E23K (n=1) I38T/M (n=2) OwH A37T (n=1) I38M (n=1) Pediatric study A(H3N2) A37T (n=1) I38T (n=15) 77 in Japan E119G (n=1) I38M (n=3) I38T (n=13) A(H3N2) and B CAPSTONE-2 HR 290 E23K (n=1) I38M (n=1) I38N (n=1) • PA/I38X viral variants not detected in placebo treated patients and occur very rarely among circulating viruses, PA/I38T not detected Hayden FG, et al.
Load more

Recommended publications
  • Microorganisms-07-00521-V2.Pdf
    microorganisms Review Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Cristian-Marian Popescu 1,* , Aurora Livia Ursache 2, Gavriela Feketea 1 , Corina Bocsan 3, Laura Jimbu 1, Oana Mesaros 1, Michael Edwards 4,5, Hongwei Wang 6, Iulia Berceanu 7, Alexandra Neaga 1 and Mihnea Zdrenghea 1,7,* 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes str., 400012 Cluj-Napoca, Romania; [email protected] (G.F.); [email protected] (L.J.); [email protected] (O.M.); [email protected] (A.N.) 2 The Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Calea Mănăs, tur 3-5, 400372 Cluj-Napoca, Romania; [email protected] 3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Ha¸tieganuUniversity of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; [email protected] 4 National Heart and Lung Institute, St Mary’s Campus, Imperial College London, London W2 1PG, UK; [email protected] 5 Medical Research Council (MRC) and Asthma UK Centre in Allergic Mechanisms of Asthma, London W2 1PG, UK 6 School of Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China; [email protected] 7 Department of Hematology, Ion Chiricuta Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; [email protected] * Correspondence: [email protected] (C.-M.P.); [email protected] (M.Z.) Received: 8 October 2019; Accepted: 31 October 2019; Published: 2 November 2019 Abstract: Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine.
    [Show full text]
  • Current and Novel Approaches in Influenza Management
    Review Current and Novel Approaches in Influenza Management Erasmus Kotey 1,2,3 , Deimante Lukosaityte 4,5, Osbourne Quaye 1,2 , William Ampofo 3 , Gordon Awandare 1,2 and Munir Iqbal 4,* 1 West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra P.O. Box LG 54, Ghana; [email protected] (E.K.); [email protected] (O.Q.); [email protected] (G.A.) 2 Department of Biochemistry, Cell & Molecular Biology, University of Ghana, Legon, Accra P.O. Box LG 54, Ghana 3 Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana; [email protected] 4 The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK; [email protected] 5 The University of Edinburgh, Edinburgh, Scotland EH25 9RG, UK * Correspondence: [email protected] Received: 20 May 2019; Accepted: 17 June 2019; Published: 18 June 2019 Abstract: Influenza is a disease that poses a significant health burden worldwide. Vaccination is the best way to prevent influenza virus infections. However, conventional vaccines are only effective for a short period of time due to the propensity of influenza viruses to undergo antigenic drift and antigenic shift. The efficacy of these vaccines is uncertain from year-to-year due to potential mismatch between the circulating viruses and vaccine strains, and mutations arising due to egg adaptation. Subsequently, the inability to store these vaccines long-term and vaccine shortages are challenges that need to be overcome. Conventional vaccines also have variable efficacies for certain populations, including the young, old, and immunocompromised.
    [Show full text]
  • Study Protocol
    NCT03376321 Janssen Research & Development * Clinical Protocol A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection Protocol 63623872FLZ3001; Phase 3 AMENDMENT 2 JNJ-63623872-ZCD Pimodivir *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2017-002156-84 Status: Approved Date: 11 June 2019 Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV EDMS number: EDMS-ERI-121941709, 10.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them.
    [Show full text]
  • Study Protocol
    NCT03381196 Janssen Research & Development * Clinical Protocol A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection who Are at Risk of Developing Complications Protocol 63623872FLZ3002; Phase 3 AMENDMENT 1 JNJ-63623872-ZCD Pimodivir *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2017-002217-59 Status: Approved Date: 9 February 2018 Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV EDMS number: EDMS-ERI-121910908, 6.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them.
    [Show full text]
  • To Download a Copy of Agencyiq's COVID-19 Development Tracker
    Development tracker: The drugs and vaccines in development for COVID-19 The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections. Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 140 medical product candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans. Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products is far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective. Highlights: 95+ 45+ 24+ 40+ Therapeutic medical Vaccines in development Products already approved Products already in clinical products in development for other indications development (6 vaccines, 34 therapies) Last updated 8 April 2020.
    [Show full text]
  • Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018
    REPORT 2019 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway Usage of Antivirals and the Occurrence of Antiviral resistance in Norway 2018 RAVN Resistensovervåkning av virus i Norge Resistance against antivirals in Norway 2 Published by the Norwegian Institute of Public Health Division of Infection Control and Environmental Health Department for Infectious Disease registries October 2019 Title: Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. RAVN Ordering: The report can be downloaded as a pdf at www.fhi.no Graphic design cover: Fete Typer ISBN nr: 978-82-8406-032-3 Emneord (MeSH): Antiviral resistance Any usage of data from this report should include a specific reference to RAVN. Suggested citation: RAVN. Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. Norwegian Institute of Public Health, Oslo 2019 Resistance against antivirals in Norway • Norwegian Institute of Public Health 3 Table of contents Introduction _________________________________________________________________________ 4 Contributors and participants __________________________________________________________ 5 Sammendrag ________________________________________________________________________ 6 Summary ___________________________________________________________________________ 8 1 Antivirals and development of drug resistance ______________________________________ 10 2 The usage of antivirals in Norway
    [Show full text]
  • Unconventional Viral Gene Expression Mechanisms As Therapeutic Targets
    Review Unconventional viral gene expression mechanisms as therapeutic targets https://doi.org/10.1038/s41586-021-03511-5 Jessica Sook Yuin Ho1,3, Zeyu Zhu1,3 & Ivan Marazzi1,2 ✉ Received: 8 June 2020 Accepted: 22 March 2021 Unlike the human genome that comprises mostly noncoding and regulatory sequences, Published online: 19 May 2021 viruses have evolved under the constraints of maintaining a small genome size while expanding the efciency of their coding and regulatory sequences. As a result, viruses Check for updates use strategies of transcription and translation in which one or more of the steps in the conventional gene–protein production line are altered. These alternative strategies of viral gene expression (also known as gene recoding) can be uniquely brought about by dedicated viral enzymes or by co-opting host factors (known as host dependencies). Targeting these unique enzymatic activities and host factors exposes vulnerabilities of a virus and provides a paradigm for the design of novel antiviral therapies. In this Review, we describe the types and mechanisms of unconventional gene and protein expression in viruses, and provide a perspective on how future basic mechanistic work could inform translational eforts that are aimed at viral eradication. Expression of a gene in the human genome is a multistep and heavily (for example, alternative splicing) or use unique strategies. Here we regulated process that resembles a production line. Protein-coding describe the diverse ways by which viral genomes give rise to genes and genes are transcribed almost exclusively by RNA polymerase II (RNAPII). proteins that deviate from the canonical framework of human genes, During transcription, quality-control checkpoints are implemented to restricting our analyses to eukaryotes and their viruses.
    [Show full text]
  • Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action
    University of Louisville Journal of Respiratory Infections REVIEW ARTICLE Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action Julio A. Ramirez1* DOI: 10.18297/jri/vol3/iss1/9 Received Date: February 1, 2019 Accepted Date: March 13, 2019 https://ir.library.louisville.edu/jri/vol3/iss1/ Affiliations: 1University of Louisville, Divison of Infectious Diseases, School of Medicine This original article is brought to you for free and open access by ThinkIR: The University of Louisville’s Institutional Repository. It has been accepted for inclusion in The University of Louisville Journal of Respiratory Infections by an authorized editor of ThinkIR. For more information, please contact [email protected]. Recommended Citation: Ramirez, Julio A. (2019) “Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action,” The University of Louisville Journal of Respiratory Infections: Vol. 3 : Iss. 1 , Article 9. Introduction Due to significant research efforts in the field of influenza cells (Figure 1: Attachment). Since sialic acids are abundant therapy, in the near future we will have a series of new antivirals in membranes of human epithelial cells, the virus has multiple to treat patients with influenza. Most likely, hospitalized receptors to attach. The binding of the hemagglutinin to sialic patients with influenza pneumonia as well as other severe acid triggers the next step of viral entry into the cell. forms of influenza will be managed with combination antiviral therapy. During the selection of antivirals, it will be important Step 2. Endocytosis of the influenza virus for physicians to have a clear understanding of the mechanisms of action of anti-influenza medications.
    [Show full text]
  • A Meeting Report from the 6Th Isirv Antiviral Group Conference T
    Antiviral Research 167 (2019) 45–67 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference T ∗ John H. Beigela, , Hannah H. Namb, Peter L. Adamsc, Amy Kraffta, William L. Inced, Samer S. El-Kamaryd, Amy C. Simse a National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA bNorthwestern University, Feinberg School of Medicine, Chicago, IL, USA c Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), Washington, DC, USA d Division of Antiviral Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S Food and Drug Administration, Silver Spring, MD, USA e Gillings School of Global Public Health, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA ARTICLE INFO ABSTRACT Keywords: The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv- Influenza AVG) conference in Rockville, Maryland, November 13–15, 2018. The three-day program was focused on Respiratory syncytial virus therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including Coronavirus MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several Antiviral therapy influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, Host-directed therapeutics pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies in- cluding nitazoxanide, eritoran, and diltiazem.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Epidemics of Infectious Diseases in Human History. Antiviral Drugs and Vaccines in the Development Stage to Protect Against Coronavirus SARS- Cov-2
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/340233668 Epidemics of Infectious Diseases in Human History. Antiviral Drugs and Vaccines in the Development Stage to Protect Against Coronavirus SARS- CoV-2 Article · March 2020 CITATIONS READS 0 416 1 author: Athanasios - Valavanidis National and Kapodistrian University of Athens 312 PUBLICATIONS 5,281 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Air Pollution by Particulate Mater (PM10, PM2.5 and <PM2.5) and Adverse Health Effects on Urban Populations View project Research and Development ( R&D ) expenditure in developed countries and the role of universities in economic growth, innovation , expertise in manpower. Statistical data of the last decade, including Greece View project All content following this page was uploaded by Athanasios - Valavanidis on 27 March 2020. The user has requested enhancement of the downloaded file. WEBSITE: chem-tox-ecotox.org/ScientificReviews 27 March 2020 SCIENTIFIC REVIEWS Epidemics of Infectious Diseases in Human History. Antiviral Drugs and Vaccines in the Development Stage to Protect Against Coronavirus SARS-CoV-2 Athanasios Valavanidis Department of Chemistry, National and Kapodistrian University of Athens, University Campus Zografou, 15784 Athens, Greece E-mail : [email protected] Abstract. Infectious diseases have plagued humanity since the earliest days of civilizations. Civilizations and subsequent history have been altered profoundly by the outbreak of pathogenic infectious diseases that decimated societies and killed millions of people. The formation of agrarian communities facilitated and increased the spread of infectious diseases. Widespread trade created new opportunities for human and animal interactions that sped up such epidemics.
    [Show full text]
  • Supplementary Information Table S1. Approved, Investigational
    Supplementary information Table S1. Approved, investigational and experimental antiviral agents and their side effects (if known). Agent Status Virus Potential target Reference* Side effects, if known Abacavir Approved HIV-1 HIV-1 RT DB01048 Allergic reactions, lactic acidosis, liver toxicity, risk of heart attack, nausea, vomiting, lethargy, fever, headache, HIV-2 HIV-2 RT diarrhea. Aciclovir Approved HSV-1 HSV-1 DNA pol DB00787 HSV-2 HSV-2 DNA pol Nausea, diarrhea, headache, vomiting, VZV VZV DNA pol kidney toxicity, low platelets. Weakness, headache, fever, increased cough, nausea, vomiting, diarrhea, skin Adefovir Approved HBV HBV RT DB13868 rash. Skin reactions, photosensitivity, Alitretinoin Approved HHV-8 Human RARA DB00523 numbness, muscle aches. Nausea, diarrhea, constipation, headache, insomnia, blurred vision, loss of Amantadine Approved FLUAV FLUAV M2 DB00915 coordination, rash, confusion. Gastrointestinal symptoms (nausea, abdominal pain, diarrhea), paresthesia, Amprenavir Approved HIV-1 HIV-1 RT DB00701 depression, rash. Flu-like symptoms, hair loss, nausea, rash, Asunaprevir Approved HCV HCV protease DB11586 anemia, clotting problems, liver toxicity. Atazanavir Approved HIV-1 HIV-1 RT DB01072 Arrhythmia, rash, liver toxicity, flu-like HIV-2 HIV-2 RT symptoms. BCX4430 Approved HCV HCV RNA pol DB11676 N. a. Brivudine Approved HSV-1 HSV-1 DNA pol DB03312 Nausea, headache, lowered blood cell VZV VZV DNA pol counts, liver toxicity, allergic reactions. Headache, nausea, vomiting, abdominal Cidofovir Approved CMV CMV DNA pol DB00369 pain, rash, liver toxicity. Cobicistat Approved HIV-1 HIV-1 integrase DB09065 Nausea, dizziness, liver and kidney HIV-2 HIV-2 integrase toxicity, Headache, nausea, diarrhea, insomnia, Daclatasvir Approved HCV HCV NS5A DB09102 rash, anemia.
    [Show full text]